This diagram illustrates the central thesis: diverse longevity-promoting interventions — from mitochondrial ETC mutations to dietary restriction to hypoxia — all funnel through overlapping transcription factor networks to upregulate a single effector enzyme, FMO-2. The remarkable specificity (only fmo-2, not fmo-1/3/4/5) makes it an exceptionally attractive therapeutic target.
Single effector. Unlike complex aging pathways with dozens of mediators, FMO-2 is a single enzyme where multiple longevity signals converge — making it an unusually clean drug target.
Highly conserved. FMOs are present from nematodes to humans (5 human FMO genes). Mouse FMOs are induced by caloric restriction, rapamycin, and other lifespan-extending interventions.
Already druggable. FMO-2 induction can be used as a screening biomarker — 9 of 80 tested compounds both induced fmo-2 and extended C. elegans lifespan (Huang et al. 2024).
Metabolic rewiring. FMO-2 doesn't just detoxify — it fundamentally rewires one-carbon metabolism and tryptophan catabolism, two pathways independently linked to longevity (Choi et al. 2023).
Genetic epistasis: fmo-2 RNAi or mutation shortens lifespan of clk-1, isp-1, and nuo-6 mutants but has no effect on wild-type — proving FMO-2 mediates the longevity benefit.
Transcriptional specificity: Only fmo-2 (not fmo-1, -3, -4, -5) is upregulated in Group 1 longevity mutants (clk-1, isp-1, nuo-6, daf-2, glp-1, sod-2).
7-pathway convergence: Disrupting DAF-16, PMK-1, SKN-1, CEH-23, AAK-2, HIF-1, or ELT-2 each independently reduces both lifespan AND fmo-2 expression in clk-1 mutants.
Cell non-autonomous signaling: Neuronal HIF-1 sends a serotonergic signal (TPH-1 → SER-7) to the intestine, where FMO-2 is activated (Leiser et al. 2015, Science).
FMOs are NADPH-dependent monooxygenases that use a flavin adenine dinucleotide (FAD) cofactor to catalyze the oxidation of soft nucleophilic centers in substrates — typically nitrogen, sulfur, phosphorus, or selenium atoms.
Originally classified as xenobiotic detoxification enzymes (metabolizing drugs, pesticides, and dietary compounds), FMO-2 has been revealed to have a far more fundamental role: rewiring endogenous metabolism to promote longevity.
Key reaction: S + O₂ + NADPH → S=O + H₂O + NADP⁺
Among 5 C. elegans FMOs, only fmo-2 is specifically upregulated in Group 1 longevity mutants (those with mitochondrial impairment or reduced insulin/IGF signaling).
Group 2 longevity mutants (eat-2 dietary restriction, osm-5 sensory) actually show decreased fmo-2, suggesting distinct mechanistic classes.
The recently characterized fmo-4 promotes longevity through a separate mechanism: ER-to-mitochondria calcium regulation (Tuckowski et al. 2025, eLife). This suggests the FMO family has diversified longevity functions.
Group 1 mutants (sod-2, clk-1, isp-1, nuo-6, daf-2, glp-1) show robust fmo-2 upregulation. Group 2 mutants (eat-2, osm-5) show downregulation. Group 3 (ife-2) shows no change. Data from Van Raamsdonk 2026.
Each gene shown is required for BOTH the long lifespan AND the upregulation of fmo-2 in clk-1 mitochondrial mutants. Bars show relative lifespan reduction when each gene is disrupted. All 7 pathways converge on FMO-2 as a common downstream effector.
| Mutant | Gene Function | ETC Position | fmo-2 Upregulation | fmo-2 RNAi Effect | Mechanism |
|---|---|---|---|---|---|
| clk-1 | Coenzyme Q biosynthesis | CoQ → Complex I/II | ↑↑↑ Significant | Shortens lifespan | Impaired ubiquinone synthesis |
| isp-1 | Iron-sulfur protein (Rieske) | Complex III subunit | ↑↑↑ Significant | Shortens lifespan | Reduced Q cycle electron transfer |
| nuo-6 | NDUFB4 (NADH dehydrogenase) | Complex I subunit | ↑↑↑ Significant | Shortens lifespan | Reduced Complex I activity |
Tryptophan was identified as a validated endogenous substrate for FMO-2. FMO-2 overexpression decreases tryptophan levels in C. elegans, and this decrease is also seen in mammalian FMO overexpression models.
Tryptophan catabolism connects to the kynurenine pathway, which generates NAD⁺ precursors and neuroactive metabolites — both independently linked to aging.
FMO-2 rewires OCM by decreasing the SAM/SAH ratio, reducing methylation capacity. Computer modeling identified this decreased methylation flux as the single OCM change sufficient to explain FMO-2's longevity benefits.
Genetically modifying OCM enzymes (metr-1/sams-1) interacts with fmo-2 for lifespan, confirming functional linkage.
| Species | FMO Genes | Key Longevity FMO | Tissue Expression | Evidence for Longevity Role |
|---|---|---|---|---|
| C. elegans | fmo-1 to fmo-5 | fmo-2 (intestine) | Intestine, hypodermis | ★★★★★ Required for multiple longevity pathways |
| Mus musculus | Fmo1 to Fmo5 | Fmo4, Fmo5 upregulated | Liver, kidney, lung | ★★★★ Induced by CR, rapamycin, pro-longevity drugs |
| Homo sapiens | FMO1 to FMO5 | FMO3 (liver), FMO5 | Liver, kidney, brain | ★★ Drug metabolism (trimethylamine); longevity role unknown |
Mouse fibroblast screening (Huang et al. 2024): 80 compounds previously shown to improve stress resistance in mouse cells were tested. Compounds that extended C. elegans lifespan also induced Fmo4 and Fmo5 in mouse fibroblasts.
ITP drugs: Known lifespan-extending drugs from the NIA Interventions Testing Program (acarbose, 17α-estradiol, rapamycin) induce FMO expression in mouse tissues.
Caloric restriction robustly induces hepatic Fmo gene expression in mice, paralleling the DR → FMO-2 pathway in worms.
Human FMO3 is best known for converting trimethylamine (TMA) to TMAO. Elevated TMAO is associated with cardiovascular disease — seemingly at odds with a pro-longevity role.
However, (1) the worm longevity FMO is fmo-2, not fmo-3; (2) FMO substrate specificity differs; (3) the longevity mechanism operates through metabolic rewiring of endogenous substrates, not xenobiotic clearance.
The human longevity-relevant FMO isoform likely differs from FMO3. FMO1, FMO4, and FMO5 remain under-explored for aging phenotypes.
Step 1: Screen 80 compounds for stress resistance in mouse fibroblasts (UM-HET3 mice) → identify hits
Step 2: Test hits for fmo-2::GFP reporter induction in C. elegans → 19 compounds induce fmo-2, 10 induce >2×
Step 3: Lifespan assays on high-induction hits → 9 of 10 extend lifespan
Step 4: Pathway epistasis — test with hif-1 and eat-2 mutants → identify hypoxia vs DR routes
Step 5: Cross-species validation — confirm Fmo4/Fmo5 induction in mouse fibroblasts
This establishes fmo-2 as a robust, scalable screening platform for pro-longevity drug discovery.
Estimate the potential FMO-2 pathway activation based on intervention parameters. Adjust the sliders to model different longevity scenarios in C. elegans.
- Van Raamsdonk JM. Mild mitochondrial impairment activates overlapping longevity pathways converging on FMO-2. bioRxiv. 2026. DOI: 10.64898/2026.02.10.705198
- Leiser SF, Miller H, Rossner R, et al. Cell nonautonomous activation of flavin-containing monooxygenase promotes longevity and health span. Science. 2015;350(6266):1375-1378. DOI: 10.1126/science.aac9257
- Choi HS, Bhat A, Howington MB, et al. FMO rewires metabolism to promote longevity through tryptophan and one carbon metabolism in C. elegans. Nat Commun. 2023;14:562. DOI: 10.1038/s41467-023-36181-0
- Huang S, Cox RL, Tuckowski A, et al. Fmo induction as a tool to screen for pro-longevity drugs. GeroScience. 2024;46:4689-4706. DOI: 10.1007/s11357-024-01207-y
- Tuckowski AM, Beydoun S, Kitto ES, et al. fmo-4 promotes longevity and stress resistance via ER to mitochondria calcium regulation. eLife. 2025;13:RP99971. DOI: 10.7554/eLife.99971
- Bennett CF, Kwon JJ, Chen C, et al. Transaldolase inhibition impairs mitochondrial respiration and induces a starvation-like longevity response. PLoS Genet. 2017;13:e1006695. DOI: 10.1371/journal.pgen.1006695
- Jakovljević S, Radojević D, Bajić SS, et al. Bacterial exopolysaccharides mediate activation of FMO-2 to extend lifespan. Cell Commun Signal. 2025;24:9. DOI: 10.1186/s12964-025-02567-4
- Said M, Ferrara BT, Aprodu A, et al. Transcriptional analysis of C. elegans fmos at different life stages and their roles in ageing. Mol Genet Genomics. 2024;299:113. DOI: 10.1007/s00438-024-02201-x
- Goh GYS, Winter JJ, Bhanshali F, et al. NHR-49/HNF4 integrates fatty acid metabolism with protective transcriptional response. Aging Cell. 2018;17:e12743. DOI: 10.1111/acel.12743
- Mehta R, Steinkraus KA, Sutphin GL, et al. Proteasomal regulation of the hypoxic response modulates aging. Science. 2009;324:1196-1198.
- Zhang Y, Shao Z, Zhai Z, et al. The HIF-1 hypoxia-inducible factor modulates lifespan in C. elegans. PLoS One. 2009;4:e6348.
- Lee SJ, Hwang AB, Kenyon C. Inhibition of respiration extends C. elegans life span via ROS that increase HIF-1 activity. Curr Biol. 2010;20:2131-2136.
- Wu Z, Senchuk MM, Dues DJ, et al. Mitochondrial UPR transcription factor ATFS-1 promotes longevity. BMC Biology. 2018;16:147.
- Kenyon CJ. The genetics of ageing. Nature. 2010;464:504-512.
- Lapierre LR, De Magalhaes Filho CD, McQuary PR, et al. The TFEB orthologue HLH-30 regulates autophagy and modulates longevity. Nat Commun. 2013;4:2267.
- Blackwell TK, Steinbaugh MJ, Hourihan JM, et al. SKN-1/Nrf as a target for manipulation of longevity and healthspan. Exp Gerontol. 2015;68:72-81.
- Taubert S, Van Gilst MR, Hansen M, Yamamoto KR. A Mediator subunit, MDT-15/MED15, integrates regulation of fatty acid metabolism. Genes Dev. 2006;20:1137-1149.
- Pathare PP, Lin A, Bornfeldt KE, Taubert S, Van Gilst MR. Coordinate regulation of lipid metabolism by novel nuclear receptor partnerships. PLoS Genet. 2012;8:e1002645.
- Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A. 2011;66:191-201.
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186:243-278.